135 related articles for article (PubMed ID: 38381686)
1. Semaglutide and Cardiovascular Outcomes.
Neves JS; Leite AR; Ferreira JP
N Engl J Med; 2024 Feb; 390(8):767-768. PubMed ID: 38381686
[No Abstract] [Full Text] [Related]
2. Comment on: Semaglutide and cardiovascular outcomes in obesity without diabetes.
Basolo A; Fierabracci P; Salvetti G; Santini F
J Endocrinol Invest; 2024 May; 47(5):1047-1049. PubMed ID: 38157134
[No Abstract] [Full Text] [Related]
3. Semaglutide and Cardiovascular Outcomes.
Campbell LA; Jenkins AV; Jackson CD
N Engl J Med; 2024 Feb; 390(8):767. PubMed ID: 38381685
[No Abstract] [Full Text] [Related]
4. Semaglutide and Cardiovascular Outcomes.
Belkhouribchia J
N Engl J Med; 2024 Feb; 390(8):767. PubMed ID: 38381684
[No Abstract] [Full Text] [Related]
5. Semaglutide and Cardiovascular Outcomes.
Belalcazar LM; Kuo YF
N Engl J Med; 2024 Feb; 390(8):766-767. PubMed ID: 38381683
[No Abstract] [Full Text] [Related]
6. Semaglutide and Cardiovascular Outcomes.
Taqueti VR; Shaw LJ
N Engl J Med; 2024 Feb; 390(8):766. PubMed ID: 38381682
[No Abstract] [Full Text] [Related]
7. Diabetes: Cardiovascular benefits of semaglutide.
Lim GB
Nat Rev Cardiol; 2016 Dec; 13(12):697. PubMed ID: 27708277
[No Abstract] [Full Text] [Related]
8. Semaglutide, a newly available glucagon-like peptide receptor agonist, shows remarkable favorable effects in hemodialysis patients with obesity and Type 2 diabetes.
Saito S; Nakao T
Ther Apher Dial; 2022 Feb; 26(1):242-243. PubMed ID: 33830659
[No Abstract] [Full Text] [Related]
9. Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials.
Mellbin LG; Bhatt DL; David JP; Ekström K; Petrie MC; Rasmussen S; Vilsbøll T
Eur Heart J; 2024 Apr; 45(15):1371-1374. PubMed ID: 38416593
[No Abstract] [Full Text] [Related]
10. Semaglutide and Cardiovascular Outcomes. Reply.
Lincoff AM; Ryan DH; Esbjerg S
N Engl J Med; 2024 Feb; 390(8):768-769. PubMed ID: 38381687
[No Abstract] [Full Text] [Related]
11. Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity.
Villela R; Correa R
J Investig Med; 2022 Jan; 70(1):3-4. PubMed ID: 34949728
[No Abstract] [Full Text] [Related]
12. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity.
Newsome P; Francque S; Harrison S; Ratziu V; Van Gaal L; Calanna S; Hansen M; Linder M; Sanyal A
Aliment Pharmacol Ther; 2019 Jul; 50(2):193-203. PubMed ID: 31246368
[TBL] [Abstract][Full Text] [Related]
13. Reducing cardiovascular outcomes with semaglutide: a metabolic route for a SELECT few.
Liuzzo G; Patrono C
Eur Heart J; 2024 Feb; 45(8):570-571. PubMed ID: 38103177
[No Abstract] [Full Text] [Related]
14. Semaglutide Improved Cardiovascular Health in People Without Diabetes.
Harris E
JAMA; 2023 Dec; 330(23):2241-2242. PubMed ID: 38019508
[No Abstract] [Full Text] [Related]
15. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I
Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6.
Nauck MA; Quast DR
Front Endocrinol (Lausanne); 2021; 12():645566. PubMed ID: 33854484
[TBL] [Abstract][Full Text] [Related]
17. Eligibility for and Preventive Potential of Semaglutide in Overweight and Obese Patients With Myocardial Infarction.
Hansen MK; Olesen KKW; Gyldenkerne C; Thrane PG; Stødkilde-Jørgensen N; Mortensen MB; Maeng M
J Am Coll Cardiol; 2024 Mar; 83(9):956-958. PubMed ID: 38418010
[No Abstract] [Full Text] [Related]
18. Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?
Doggrell SA
Expert Opin Biol Ther; 2020 May; 20(5):489-492. PubMed ID: 32005073
[No Abstract] [Full Text] [Related]
19. Effect of semaglutide on coronary atherosclerosis progression in patients with type II diabetes: rationale and design of the semaglutide treatment on coronary progression trial.
Hamal S; Cherukuri L; Shaikh K; Kinninger A; Doshi J; Birudaraju D; Budoff MJ
Coron Artery Dis; 2020 May; 31(3):306-314. PubMed ID: 32271261
[TBL] [Abstract][Full Text] [Related]
20. [The glucagon-like peptide-1 receptor-agonist semaglutide].
Boje AD; Juhl CR; Torekov SS; Madsbad S
Ugeskr Laeger; 2019 Oct; 181(41):. PubMed ID: 31610830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
